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Abstract
Work-related upper limb disorders (WMSDs), also known as repetitive strain injuries, 
affect a large subsection of the US population. These disorders are a significant source 
of injury, morbidity, loss of work, and pain. We have developed a rat model of upper 
extremity repetitive work at high forces, and observed exposure-dependent increased 
inflammatory responses in all tissues involved in performing the task. A 2- to 8-week 
regimen of oral ibuprofen provided to rats while they continued to perform a high-
repetition high-force task ameliorated these inflammatory responses as well as several 
motor declines. Ibuprofen treatment also attenuated task-induced tissue fibrosis, carti-
lage degeneration, and bone osteopenia, indicating their link to inflammatory processes. 
However, ibuprofen did not significantly attenuate persistent nocifensive pain behav-
iors (reflexive grip strength results are presented) likely because of persistent increases 
in inflammatory cytokines in the spinal cord, suggestive of central sensitization. Since 
long-term ibuprofen use can induce a number of negative side effects, such as gastritis, 
multi-pronged approaches should be considered with anti-inflammatory drugs included 
for only short time periods.
Keywords: repetitive loading, work-related musculoskeletal disorders, repetitive strain 
injury, ibuprofen, osteopenia
1. Introduction
Overuse-induced musculoskeletal disorders (MSDs) are also known as overuse injuries, repet-
itive strain injuries. Diagnoses of upper extremity MSDs include muscle strain injuries, carpal 
and cubital tunnel syndromes, muscle myalgia/hyperalgesia, dorsal wrist tendinosis, lateral 
and medial epicondylopathies, rotator cuff tendinopathies, and more. These disorders often 
occur as a consequence of daily activities (both occupational and not), sports or military activi-
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
ties, and are a leading cause of pain and physical disability [1–4]. Some cases become so severe 
that simple personal tasks, such as buttoning a shirt, become difficult to impossible. Acute 
trauma may be a causal factor in some WMSDs. Yet, many result from cumulative small ampli-
tude forces occurring with overtraining, overexertion, repetitive activities, forceful actions, and 
prolonged static positioning [5–8]. Prevention is hampered by many problems [9, 10]. There 
remains a call for effective treatments for these often debilitating disorders [9, 11].
2. Current treatments for overuse—MSDs
The first line of treatment for workers in pain usually entails a prescription of non-steroidal 
anti-inflammatory drugs (NSAIDs), such as ibuprofen [12, 13]. NSAIDs are the most com-
monly used (self-care and prescribed) for acute and chronic musculoskeletal pain [14–17]. 
A survey study of 941 workers found that 84% used NSAIDs, including ibuprofen, for pain 
[17]. Forty percent of 2213 French workers reported the regular use of ibuprofen in a 1-month 
period [18]. Back and shoulder injuries and other musculoskeletal strains are largely self-
treated by migrant farm workers with rest and over-the-counter drugs, such as ibuprofen 
[14]. Rest, ice, compression, and elevation (termed RICE oftewn) are also often used to treat 
acute injuries. However, RICE has proved less effective for treatment of pain associated with 
chronic overuse—MSDs than NSAIDs. Splinting for carpal tunnel syndrome is less effective 
than surgical release or injections of steroids around the nerve [19–24], which are also not 
always effective [19–24].
3. Ibuprofen
Ibuprofen was introduced to the US market as a prescription drug to treat arthritic conditions 
in 1974, and subsequently became available over the counter in the United States in 1984. 
Despite its relatively short history as an over-the-counter medicine, it has quickly achieved 
popularity as a treatment for musculoskeletal and peripheral nerve pain, capturing up to a 
third of the over-the-counter analgesics market of the US by 2002. According to background 
information supplied by Wyeth Pharmaceuticals (a manufacturer of Advil, a brand name 
ibuprofen), this occurred principally because of its strong gastrointestinal (GI) safety profile 
that ibuprofen was approved for over-the-counter use. There are a wide variety of ibuprofen 
drugs available on the market as indicated in Table 1. Tablet, caplet, injectable, and topi-
cal forms are available. Negative side effects and major concerns will be discussed later in 
this chapter, although it should be noted that topical ibuprofen formulas are absorbed less 
into blood stream than oral forms, avoiding several side effects. However, as topical NSAID 
drugs are not systemic, they will not reduce inflammatory responses other than at the site of 
application.
Ibuprofen works by inhibiting both the constitutive cyclooxygenase (COX)-1 and the 
more inducible COX-2 enzyme. These enzymes catalyze the generation of prostanoids 
( prostaglandins PGE2 and PGF2a), prostacyclins, and thromboxanes [25, 26]. Inhibition of 
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these enzymes by ibuprofen prevents the conversion of arachidonic acid to prostaglandin H2, 
and in doing so blocks the prostaglandin-signaling pathway. Prostaglandins play an impor-
tant role in pain and inflammatory signaling, as well as have roles in maintaining kidney 
function (mainly by regulating blood flow in the glomerular capsule) and the gut mucosa, 
and cardiovascular physiological processes [26].
A steady dose of ibuprofen is considered necessary to attenuate the increase in inflammation, 
rather than just analgesic. The dose used should be lower than the maximum limit for gastro-
intestinal toxicity. Those suggested maximum limits are indicated in Table 1.
4. An operant rat model of WMSD
Several animal models have been developed to study WMSDs and have shown that repeti-
tive hand activities induce sensorimotor dysfunction [27–33]. A model developed in our 
Brand names
Ibuprofen Tablets and Caplets: Actiprofen Caplets (CA), Advil, Advil Extra Strength (CA), Advil Migraine, Anadin 
Ibuprofen (UK), Anadin Ultra (UK), Apo-Ibuprofen (CA), Arthrofen (UK), Brufen (UK), Cuprofen (UK), Extra Strength 
Motrin IB (CA), Hedex Ibuprofen (UK), Motrin, Motrin IB, Ibuprofen (CA), IBU
Active ingredient: Ibuprofen (100–800-mg tables and caplets available).
Typical dose is 200–400 mg/dose; Maximum amount is 800 mg/dose, or 3200 mg per day.
Use: Reduction of fever, pain, or inflammation from headache, dental pain, menstrual cramps, rheumatoid 
arthritis, osteoarthritis, muscle aches, minor aches, and pain.
Note: An anti-inflammatory dose is higher than an analgesic dose, and must be maintained for full 
effectiveness.
Ibuprofen PM Tablets: Advil PM, Motrin PM
Active Ingredient: Ibuprofen (200 mg) and Diphenhydramine citrate (38 mg).
Typical dose is two capsules at bedtime (also the maximum dose/day).
Use: Occasional sleeplessness when associated with minor aches and pains.
Injectable Ibuprofen: Caldolor, Calprofen (UK), and more
Active Ingredient: Ibuprofen (various doses available).
Typical dose: Intravenous infusion of 100–800 mg dose, after dilution to 4 mg/ml or less per injection.
Use: Reduction of fever; Management of mild to moderate pain, and moderate to severe pain as an adjunct 
to opioid analgesics.
Topical Ibuprofen: Ibuprofen Gel (US), Ibuleve gel (UK), Ibumousse (UK), Ibuspray (UK), and more
Active Ingredient: Ibuprofen (various doses available).
Typical dose: three to four times a day, or as directed by a doctor, with at least 4 h between applications.
Use: Muscle or rheumatic pain, backache, neuralgia; sprains, strains and sports injuries; mild arthritis.
Note: Absorbed less into blood stream when applied topically, so not thought to reduce fever or widespread 
inflammation as a consequence.
Table 1. Types of ibuprofen available.
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laboratory is a unique operant rat model of voluntary reaching and grasping (Figure 1; [7, 
34]). Using this model, we are able to examine the effects of voluntary performance of repeti-
tive low or high demand tasks on sensorimotor performance and musculoskeletal tissues [7, 
30, 35]. This model is nonsurgical and involves performance of voluntary repetitive tasks to 
induce mechanical loading of forearm tissues. Specifically, adult rats are required to volun-
tarily and repetitively reach for, grasp, and isometrically pull a handle with one forelimb to 
obtain a food reward at various reach rates and force levels determined from studies on risk 
exposure for WMSDs to humans [7, 34]. Additionally, several functional outcomes are tested 
that are similar to those tested in patients, including forepaw (hand) sensitivity, grip strength, 
and median nerve conduction velocity.
Using this rat model, we have observed early exposure-dependent changes (duration and 
task level) in inflammatory responses in the form of increased macrophages and inflamma-
tory cytokines in soft tissues involved in performing the repetitive task [7, 30, 32, 35, 36]. The 
greatest responses were observed in rats performing a high-repetition high-force (HRHF) task 
for 6–12 weeks, compared to lower demand tasks. Therefore, we picked this HRHF task regi-
men for experiments in which we tested the effectiveness of ibuprofen.
Figure 1. Rat performing HRHF repetitive reaching task. (A) Rat awaits auditory stimulus with snout in portal. (B and C) 
Rat reaches for force handle with right forepaw; left forepaw used for postural support. (D) Closer view, rat grasps and 
isometrically pulls force handle attached to force transducer (FT), until predetermined force threshold is reached and 
held for at least 50 ms. (E) Rat retrieves foot pellet reward by mouth from food trough.
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5. Testing the effectiveness of ibuprofen treatment for WMSDs
We hypothesized that an underlying inflammatory mechanism is driving many of the sen-
sorimotor declines, as are inflammation-linked fibrotic and degenerative/degradative tis-
sue changes [37]. We explored this hypothesis by treating rats with systemic ibuprofen (i.e., 
oral) at anti-inflammatory doses. The design of these experiments is shown in Figure 2, and 
included normal controls (termed NC rats) and food-restricted-only controls (termed FRC 
rats). Rats were food-restricted to body weights of 5% less than age-matched normal controls 
to motivate them to work. Subsets of food-restricted rats were trained to high-force levels to 
determine the effects of training (10 min/day, 5 days/week, for 5 weeks) in which they learn 
to pull at high-force levels (1.25 Newton’s which is approximately 60% of their maximum 
voluntary force) [7]. The trained-only rats are termed TRHF rats. Subsets of TRHF rats went 
on to perform a high-repetition high-force task regimen for 2 h/day, 3 days/week for up to 
12 weeks. Task requirements were a reach rate of 8 reaches/min and a target force of 60 ± 5% 
of their mean maximum pulling force. HRHF rats had to grasp the force lever bar and exert 
an isometric pull at the target level for at least 50 ms to receive a food reward. Half of each 
group was administered ibuprofen (Children’s Motrin Grape Flavored, Johnson & Johnson) 
in drinking water daily (a dose of 45 mg/kg body weight was used). This dose was lower 
than the maximum limit for gastrointestinal toxicity in rats, yet effective in reducing chronic 
inflammation [38]. The results of these experiments and the effectiveness (or lack thereof) are 
discussed below.
Figure 2. Experimental design. (A) Food restriction began after a 1-week period of daily handling. All rats but normal 
control (NC ± ibuprofen treatment) were food restricted to 5% less than weights of age-matched NC rats. NC and 
food-restricted control (FRC) rats rested until euthanasia at matched time points as HRHF rats. Trained and task rats 
underwent a 5-week training period (rats reached the HRHF level by last week of training). These trained-only rats 
(TRHF) were euthanized after training. Task rats performed a high-repetition high-force (HRHF) task for 12 weeks. 
NC+IBU and FRC+IBU rats received daily ibuprofen (IBU) treatment of 45 mg/kg of body weight in drinking water in 
the final 8 weeks, as did HRHF+IBU rats (arrow indicates the onset of ibuprofen treatment). TRHF+IBU rats received 
ibuprofen treatment prophylactically during training. The number of rats per group is shown at the far right.
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5.1. Ibuprofen effectively reduced tissue inflammation induced by the HRHF task and 
voluntary motor abilities
Some mechanisms examined to date in our rat model include task-induced tissue injury, 
inflammation, and fibrosis, each of which contributed to declines in grip strength by produc-
ing discomfort or affecting biomechanical strength. Evidence of tissue injury was paralleled 
by inflammatory responses, such as increased pro-inflammatory cytokines in flexor digito-
rum muscles and tendons [30–32, 39], and increased macrophages in the median nerve at the 
level of the wrist (Figure 3A, B). Elevated levels of key pro-inflammatory cytokines, IL-1beta, 
and TNF-alpha were also observed in serum of rats that had performed a HRHF task for 12 
weeks (12-week HRHF rats) (Figure 3D, E).
Treatment of rats performing a high-repetition high-force task with oral ibuprofen in weeks 
5–12 of a 12-week task regimen significantly reduced macrophage numbers and inflammatory 
cytokines in tissues and serum (Figure 3A, B, D). Ibuprofen treatment also improved HRHF-
induced declines in several voluntary work parameters, including reach rate, voluntary 
pulling force, and duration of voluntary performance (Figure 4A, B) [40, 41]. Similarly, the 
treatment of human subjects with ibuprofen before unaccustomed exercise improves muscle 
strength [42, 43]. The attenuation of voluntary reach abilities in HRHF+IBU rats in parallel 
with reduced numbers of macrophages in the median nerve (Figure 3A) [40] indicates that a 
task-induced neuralgia is contributing to voluntary motor declines seen in Figure 4A and B.
5.2. Ibuprofen treatment did not ameliorate HRHF-induced spinal cord sensitization or 
muscle hyperalgesia
However, reflexive grip strength was not rescued in 9- and 12-week HRHF+IBU rats (Figure 4C) 
[41]. This type of nocifensive motor behavior has been termed muscle hyperalgesia [44] and is a 
type of chronic pain. We postulate that ibuprofen did not rescue reflexive grip strength declines 
because it did not prevent inflammation-associated changes in the central nervous system. We 
stained cervical regions of the spinal cord for pro-inflammatory cytokine IL-1-beta levels using 
immunohistochemical methods and found that both untreated HRHF and HRHF+IBU animals 
expressed this cytokine in neurons and some glial cells at roughly the same frequency and 
intensity (Figure 5A, B, D). This was in sharp contrast to IL-1-beta immunoexpression in spinal 
cords of normal control rats, which showed an almost absence of IL-1-beta immunoexpression 
(Figure 5C). We postulate that ibuprofen, or other anti-inflammatory drug, would have to be 
provided earlier than week 4 prior to the onset of pain behaviors in order to be fully effective. 
Future studies need to consider these negative central nervous system changes to successfully 
treat chronic pain behaviors in subjects with WMSDs.
5.3. HRHF task-induced tissue fibrosis is effectively reduced by ibuprofen, indicative of 
an underlying inflammatory mechanism
Muscles undergo repetitive strain-induced fibrosis. Stauber and colleagues have shown that 
repeated muscle strains at fast velocities resulted in fibrotic myopathy with increased collagen 
content, collagen cross-links, and non-contractile tissues [45–48]. Factors and mechanisms of 
repetitive strain-induced fibrosis are still under investigation. They appear to involve transform-
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ing growth factor beta-1 (TGFB-1) and connective tissue growth factor (CTGF), a key down-
stream mediator of TGFB-1’s effects on matrix protein production [49–53]. Strong links between 
mechanical loading and increased TGFB-1 and CTGF protein levels in muscles and tendons 
in vivo, and in isolated fibroblasts and tenocytes, have been established [50, 52–55]. It is key to 
identify effective early or preventive treatments for such tissue fibrosis, as recovery from such 
tissue fibrosis is slow, even with complete cessation of strain or activity for up to 3 months [47].
CTGF production also appears to be regulated by pro-inflammatory cytokines, IL-1-beta, and 
TNF-alpha, which are also thought of as pro-fibrogenic cytokines [37, 56, 57]. Since we have 
observed that task-induced tissue inflammation precedes tissue fibrotic responses, including 
increased CTGF and collagen type 1 production [58–60], we next examined the effects of second-
ary ibuprofen treatment on fibrogenic processes in our rat model [40, 61]. In addition to successful 
reductions of tissue and serum inflammatory responses after ibuprofen treatment, we observed 
significant reductions in TGFB-1 and CTGF protein expression as well as collagen deposition in 
median nerves (Figure 3A) and flexor digitorum muscles of 6-week and 12-week HRHF+IBU rats 
(Figure 6) [40, 61]. These findings support an underlying inflammatory drive on at least some 
fibrogenic processes. This reduction in collagen deposition within and around tissue components 
of the upper extremity may also aid the return of function, such as the return of median nerve 
conduction velocity in median nerves of 12-week HRHF rats as shown in Figure 3C.
5.4. HRHF task-induced radiocarpal joint damage is ameliorated by ibuprofen treatment
Joint degeneration may occur for a number of reasons including joint trauma from increased 
repetition of joint loading, high impact joint loading, increased inflammatory processes (e.g., 
autoimmune), or pathological metabolic processes [62–64]. Radiocarpal and intercarpal joints 
of the wrist and hand, respectively, can show signs of increased incidence of hand osteoarthri-
tis in individuals involved in intense (defined as long duration, high repetition, and/or high 
force) occupationally related physical activities [65–67]. A high incidence of radiographic of 
hand osteoarthritis has been identified in middle-aged female dentists and teachers [66, 67]. 
Several studies report that increasing radiographic severity of hand osteoarthritis is associ-
ated with reduced hand function and increased pain [66, 68, 69]. Therefore, the impact of 
hand osteoarthritis is considerable [68, 69].
After 12 weeks of performing the HRHF task, untreated task animals demonstrated evi-
dence of joint inflammation (loss of proteoglycan staining as shown in Figure 7B as com-
pared to controls in Figure 7A) [70]. This loss of proteoglycan staining in untreated 12-week 
HRHF rats is captured in the form of elevated Mankin histopathological scores (Figure 7E), 
a scoring  system that also reflects a development of pannus and apoptotic cells in the joint 
cartilage. Each of these changes was indicative of task-induced joint degeneration. Serum 
biomarker testing revealed increased levels of a serum biomarker of collagen degradation, 
C1,2C (a marker of collagen type 1 and 2 degradation fragments produced by collagenase 
cleavage of type II collagen) in untreated 12-week HRHF rats [70]. Increased activated mac-
rophages, cyclooxygenase immunopositive cells, and inflammatory cytokine levels were 
detected in the distal radius, ulna, and carpal bones (the latter shown in Figure 7F, G), sup-
porting our hypothesis of an underlying inflammatory mechanism.
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Figure 3. Median nerve inflammatory and fibrotic responses as well as systemic cytokine responses. (A) Photomicrographs 
showing increased activated macrophages in the median nerve of HRHF rats (detected immunohistochemically and 
denoted with arrowheads), and width of epineurial connective tissues (CT; (double arrows)) around the median nerve 
(N) at the wrist level. Eosin counterstain. (B) Mean number of activated macrophage in the median nerve decreased with 
ibuprofen treatment provided daily in task weeks 5–12. (C) Nerve conduction velocity (NCV) in meters/second (m/sec) 
declined in HRHF rats and was rescued by ibuprofen treatment that began after task week 4 (arrow) and that continued 
though task week 12. (D and E) IL-1-beta and TNF-alpha increased systemically (in serum) in untreated HRHF rats. These 
increases were ameliorated with 8 weeks of ibuprofen treatment. Symbols: *p < 0.05 and **p < 0.01, compared to NC or FRC 
rats; &p < 0.05, compared to untreated HRHF rats. Modified with permission from Jain et al. [40], and used by permission.
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Figure 4. Voluntary and reflexive motor abilities. (A) Mean voluntary pulling force on the handle (percent of maximum pulling force) 
in grams. Across weeks of task performance, the mean voluntary pulling force was lower than target levels in untreated HRHF rats, 
yet met target levels in ibuprofen-treated rats (ibuprofen was provided in task weeks 5–12, with onset indicated by arrow). (B) Across 
the weeks, the duration of voluntary task performance decreased in untreated HRHF rats. By contrast, the duration was near target 
levels in HRHF+IBU rats in weeks 9 and 12. (C) Grip strength (maximum reflexive grip strength in grams) in the preferred reach 
limb decreased in both groups, compared to baseline naïve levels. Ibuprofen treatment only partially rescued this nocifensive motor 
behavior. *p < 0.05 and **p < 0.01, compared to week 1; &p < 0.05 and &p < 0.01, compared to target levels. Used by permission from Jain 
et al. [40] and Kietrys et al. [41].
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Figure 5. Inflammatory cytokine (IL-1-beta) immunoexpression was increased in neurons of spinal cords of both HRHF 
and HRHF+IBU rats, compared to NC rats, indicative of central sensitization (n = 4/group, images only shown). (A–D) 
IL-1-beta immunostained cells that are green in color were visible in spinal cord sections collected from the cervical 
region (since that region provides input to the median nerve innervating the hand and wrist). These cells were present 
in the intermediate and ventral horn regions of HRHF rats (A) but none were present in a control rats (C). The red color 
in panel is NeuN, a neuronal cell body marker. However, IL-1-beta immunostained cells were still visible in spinal cord 
sections of HRHF+IBU rats (D). Scale bar = 50 µm. Used by permission from Kietrys et al. [41].
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Figure 6. Fibrogenic protein levels (TGFB1, CTGF, and collagen type 1 (Col I)) were increased in forearm muscles of 
6-week HRHF rats, increases that were reduced after a 2-week treatment with ibuprofen provided in task weeks 5 and 6. 
Cross sections of flexor digitorum muscle are shown. (A–C, G) TGFB1 staining was absent in muscles of normal control 
(NC) rats shown in panel A, high in muscles of untreated 6-week HRHF rats (visible as red staining at the edges of the 
myofibers in panel B), and reduced in muscles of 6-week HRHF rats treated with ibuprofen (panel C). (D–F, H) A small 
number of CTGF-immunostained cells (red in color) were present around myofibers in NC rats as shown in panel D, 
increased in muscles of untreated 6-week HRHF rats as shown in panel E, but reduced back to control levels in muscles 
of 6-week HRHF rats treated with ibuprofen as shown in panel F. (G&F) Quantification of percentage area of muscle with 
TGFB1 and CTGF staining. *p < 0.05 and **p < 0.01, compared to NC rats; &p < 0.05 and &p < 0.01, compared to untreated 
6-week HRHF. Scale bars = 50 µm. (I, J) Collagen type 1 (Col I) immunostaining, green in color, is increased considerably 
between myofibers of 6-week HRHF rats compared to NC rats. These sections were cut longitudinally. (K,L) Another 
stain (a Masson’s trichrome stain, which shows collagen as blue) also shows that collagen deposition is increased between 
myofibers of 6-week HRHF rats compared to NC rats. Used by permission from Abdelmagid et al. [60].
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Eight weeks of ibuprofen administration reduced all of these changes, despite continued 
task performance (Figure 7). This latter finding indicates that the joint degenerative changes 
observed were a consequence of the inflammatory response induced by this high-repetition 
high-force task that was 12 weeks in duration. Each of these changes were attenuated by 
ibuprofen treatment, suggesting that such treatment is chondroprotective, at least during 
the early phases of cumulative loading-induced inflammation and degeneration in hand and 
wrist joints.
Figure 7. HRHF-induced degeneration of radiocarpal joint cartilage was attenuated by ibuprofen treatment. (A–D) Distal 
radii articular cartilage stained with safranin O and fast green from (A) untreated TRHF rat, (B) TRHF+IBU rat (trained 
controls receiving ibuprofen treatment prophylactically), (D) HRHF rats that performed the task for 12 weeks show 
dramatically reduced proteoglycan staining in the articular cartilage (red-pink safranin O staining), and (E) HRHF+IBU 
rats that performed the task for 12 weeks while receiving ibuprofen treatment (45 mg/kg body wt, daily, oral) in the last 
8 weeks. (E) Histopathological Mankin scores for distal radius articular cartilage of the reach limb in TRHF, TR+IBU, 
HRHF, and HRHF+IBU rats. (F&G) Cytokine concentrations in wrist joint (distal radius, ulna, and carpal bones) and in 
diaphysis of the radius and ulna bones, tested using ELISA. Levels of (F) IL-1-alpha and (G) IL-1-beta are shown for each 
group. *p < 0.05 and **p < 0.01, compared to NC rats (terms NORM); #p < 0.05 and ##p < 0.01, compared to untreated 6-week 
HRHF. Modified with permission from Driban et al. [70], and used by permission.
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5.5. Ibuprofen effectively ameliorated osteopenia by reducing task-induced cytokines and 
osteoclast activity in bones
Cyclical loading and high-force loads are known to affect bone quality [71–74]. However, only 
a few studies have examined changes occurring in upper extremity bones as a consequence of 
prolonged performance of occupational tasks. Bone scan studies of patients with upper extrem-
ity MSDs show increased blood flow and pooling (suggestive of inflammation) in affected 
bones, although the sensitivity and accuracy of the results were variable across studies [75–77]. 
We found that the performance of a HRHF task for 12 weeks reduced trabecular bone (Figure 
8A, B) and cortical bone thinning in the radius and ulna in untreated HRHF rats (Figure 8B) 
[39, 40]. Bone levels of IL-1-beta, an inflammatory cytokine known to stimulate osteoclastogen-
esis and activity [78, 79], increased in involved distal forelimb bones (Figure 8C). This increase 
was matched by increased osteoclasts (Figure 8C) and increases in two serum biomarkers of 
bone degradation (Trap5b, band 5 tartrate-resistant acid phosphatase, and a biomarker of 
osteoclast activity and bone resorption, and CTX1, the C-terminal telopeptide of collagen type 
I cleaved by osteoclasts during bone resorption). Thus, a 12-week task at high-repetition high-
force levels leads to a net loss of trabecular bone volume in the radius and ulna.
Figure 8. Microcomputed tomography (MicroCT), bone cytokines, and osteoclast numbers in distal radial trabecular 
region. (A) Representative transaxial microCT slices of the metaphysis of the radius and ulna (at 166 slices, 1.5 mm from 
the distal edge of their respective growth plate) from an FRC, 12-week HRHF, and 12-week HRHF+IBU rat. (B) MicroCT 
analysis of trabeculae of distal radius showing reduced trabecular bone volume (BV/TV) in HRHF rats that was rescued 
by ibuprofen treatment in task weeks 5–12. (C) IL-1-beta in forelimb bones (radius and ulna), tested using ELISA. *p < 
0.05 and **p < 0.01, compared to FRC rats; &p < 0.05, compared to untreated HRHF rats. (D) Density of osteoclasts (N.Oc.), 
normalized to bone surface (BS), of distal radial metaphyseal trabeculae. Used by permission from Jain et al. [40].
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Fortunately, systemic anti-inflammatory treatment with ibuprofen prevented these bone cata-
bolic changes (Figure 8) [40, 70]. Eight weeks of continual ibuprofen treatment reduced bone 
inflammatory cytokine levels, and osteoclast numbers and activity, despite continued task 
performance. These results suggest that bone catabolism in the untreated HRHF rats was the 
result of increased inflammatory cytokines and their activating effects on osteoclasts. In sum-
mary, forearm bone osteopenia can be one consequence of prolonged high-intensity hand and 
wrist tasks. This increase in osteopenia and perhaps even fracture risk of workers performing 
this type of task is under-investigated in human and should be the focus of future studies.
A loss of bone mineral density has been reported in metacarpal bones and distal radius and 
ulna of patients with long-term carpal tunnel syndrome [80]. Surgical release treatment for 
carpal tunnel syndrome rescues this decline in distal forearm bone mineral density [81]. Those 
authors hypothesized that nerve-compression-induced muscle weakness led to bone loss as 
a consequence of reduced muscular loading on the bone [80], since the muscles involved in 
performing hand-grip actions produce forces on forearm bones [82, 83]. In our model, ibu-
profen may be sparing bone volume by reducing osteoclastogenesis and activity as well as by 
reducing fibrotic nerve compression, thus sparing muscle activity and muscle-pulling forces 
on bones (refer to Figure 3C and 4A again).
6. Caveats of ibuprofen use
Ibuprofen treatment is inexpensive and readily available over the counter. Yet, its use should 
be limited to short-term treatments (we have tested only up to 8 weeks). Ibuprofen medica-
tion may inhibit skeletal muscle hypertrophy and adaptation [42, 84–86], although a more 
recent study shows no effect of ibuprofen on muscle hypertrophy [43]. Long-term use of 
 ibuprofen-related NSIADs could increase gastrointestinal bleeding, renal toxicity, risk of 
myocardial infarction, and hypertension [87, 88]. NSAIDs are also not always successful for 
long-term treatment of pain and dysfunction [16], similar to our results with reflexive grip 
strength.
7. New treatment directions
It is unlikely that a single drug will be effective in treating all WMSDs since their develop-
ment is multi-factorial. Multipronged treatment should be developed that are individualized 
to the subject for complete reversal of WMSD-induced tissue inflammation/fibrosis/degen-
eration and recovery of function. Figure 9 shows various points of interventional treatment, 
indicating that early treatment is needed to alter acute inflammatory responses, while chronic 
inflammatory responses are accompanied by several signs and symptoms of chronic pain 
and should be treated with secondary anti-inflammatory drugs such as ibuprofen or anti-
tumor necrosis factor alpha drugs [89]. The latter drugs have yet to be tested in subjects with 
WMSDs, but have been tested in our animal model and show fair to strong efficacy [39, 61]. In 
subjects with chronic or persistent pain, negative neuroplasticity in the CNS, termed central 
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 sensitization, may have occurred. Treatment options of such central sensitization should be 
explored carefully in future studies to reduce chronic pain. At the right side of this figure, we 
show the onset of fibrosis, which may compress and damage axons (such as in carpal tun-
nel syndrome), and tether tissues. We are currently exploring options of blocking fibrogenic-
signaling pathways in our rat model.
One new non-pharmaceutical direction may be modeled manual therapy. A recent review 
examined the effectiveness of exercise versus several types of mobilization methods for 
the treatment of carpal tunnel syndrome and concluded that there was only poor support 
[90]. However, two recent pilot studies examined massage therapy methods specifically 
and observed reduced symptoms of discomfort and increased strength post treatment in 
patients being treated for carpal tunnel syndrome [91, 92]. Another type of massage termed 
“sports massage’ has been used to treat post-exertional muscle soreness, which is also known 
as delayed onset muscle soreness (DOMS). While the clinical utility of sports massage for 
DOMS is supported overall, a comprehensive review of the literature by Moraska in 2005 
shows its effectiveness in some studies and a lack thereof in others [93]. Perhaps, this is 
because sports massage therapy treatment is typically short term. With regard to the use 
Figure 9. Summary of results and possible points of intervention indicated. Repetitive tasks can cause local injury and 
acute inflammation that could be prevented with reduced loads. Acute and chronic inflammation can be treated by 
prophylactic and secondary ibuprofen treatment at anti-inflammatory doses. Means to treat fibrosis are still under 
investigation as are most effective ways to rescue persistent sensorimotor declines. Abbreviations: CTGF = connective 
tissue growth factor; IL-1 = interleukin 1; Macs = macrophages; TNF = tumor necrosis factor; TGFB1 = transforming 
growth factor beta 1. Modified and used by permission from Barr and Barbe [89].
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of massage therapies for individuals with repetitive motion disorders, clinicians should be 
aware that these disorders are not acute in nature. Instead, repetitive motion disorders are 
the consequence of underlying tissue changes that take weeks to years. It is unlikely that a 
single, short-term treatment will be effective.
Because we could not identify any studies using manual therapies for WMSDs (other than car-
pal tunnel syndrome), we recently performed a study examining the effectiveness of modeled 
manual therapy (MMT) as a treatment for symptoms of discomfort, reduced grip strength, 
and increased tissue fibrosis occurring in forearms of rats performing a HRHF task for 12 
weeks [33]. We began the MMT immediately post training to the high-force level, a time point 
when the rats began to display signs and symptoms consistent with WMSDs. Results were com-
pared to untreated HRHF rats and to age-matched control rats. The MMT protocol included 
a mixture of manual therapy submodalities: gentle mobilization, skin rolling, and myofascial 
release (deep massage) of the forearm flexor compartment; joint mobilization of the wrist (gentle 
rotation and traction of the wrist); and stretching of the entire upper limb from the shoulder to 
the fingers. The therapy was provided 5 days per week for 12 weeks, while the animals per-
formed the HRHF task for a food reward (as above, for 3 days/week, 2 h/day, in 30-min sessions). 
Compared to untreated HRHF rats, the HRHF rats receiving the MMT (called HRHF-MMT rats) 
showed significantly fewer behaviors suggestive of discomfort and had increased numbers of 
successful reaches. Grip strength had decreased significantly post training to the high-force lev-
els, compared to the rats’ naïve levels. However, the MMT protocol improved grip strength 
within 2 weeks of treatment, an improvement that continued through week 12 despite continued 
performance of the HRHF task by the HRHF-MMT rats. An examination of tissues post euthana-
sia showed decreased nerve and connective tissue fibrosis, and decreased collagen and TGF-B1 
in the 12-week HRHF rats, compared to the untreated HRHF rats. These observations support 
further investigation of manual therapy as a preventative for repetitive motion disorders.
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